证券代码：301211 证券简称：亨迪药业 公告编号：2024-056 湖北亨迪药业股份有限公司 关于部分募集资金投资项目延期的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2021]3639 号文核准，亨迪药业向社会 公开发行人民币普通股（A 股）6,000.00 万股，发行价格为每股 25.80 元，募集资 金总额为人民币 1,548,000,000.00 元，扣除发行费用后募集资金净额为人民币 1,400,732,340.85 元。募集资金已于 2021 年 12 月 16 日划至公司指定账户。大信会 计师事务所（特殊普通合伙）于 2021 年 12 月 16 日对公司首次公开发行股票的 资金到位情况进行了审验，并出具了大信验字[2021]第 2-10059 号《验资报告》。 募集资金到账后，公司对募集资金进行了专户存储，并与保荐机构、存放募 集资金的银行签署了募集资金专户存储监管协议。 二、募集资金使用情况说明 公司募集资金投资项目已经 2020 年第一届董事会第二次会议、2020 年第 ...

2024年12月22日上午，湖北亨迪药业股份有限公司武汉研究院暨武汉亨迪原料药和制剂产品研发项目落 成典礼在武汉光谷南大健康产业园隆重举行。公司实际控制人新理益集团董事长刘益谦先生，亨迪药业 董监高，以及各界嘉宾一起见证了这一盛况。 亨迪药业董事长程志刚表示，亨迪药业一贯重视新技术投入和新品种研发，上市三年来持续加大研发投 入，累计投入1亿多元，成功开发了几十个品种，其中20个品规已经申报到国家药监局，目前已获得硫 酸阿托品原料药、醋酸阿比特龙原料药、布洛芬颗粒（0.2g）、布洛芬片（0.1g，0.2g）、托拉塞米片 （5mg，10mg）、米力农注射剂（5ml：5mg，10ml：10mg）等批文。公司坚持自主创新，申报并获得 多项国家发明专利，2023年公司获得"国家知识产权优势企业"荣誉称号，并连续4年获得中国医药 CDMO20强。未来武汉研究院将按照公司原料药制剂一体化的发展战略，致力打造一流科研中心，建设 绿色化学、连续流和手性合成等高端技术平台，高效研发原料药和制剂新品种，不断丰富产品管线，增 强公司在市场上的抗风险能力。同时借助武汉的区位优势和人才优势，吸引大量有创新力的高学历人 才，提升公司研发团 ...

湖北亨迪药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况 证券代码：301211 证券简称：亨迪药业 公告编号：2024-053 湖北亨迪药业股份有限公司（以下简称"公司"） 股票于 2024 年 10 月 25 日、2024 年 10 月 28 日、2024 年 10 月 29 日，股票交易 连续 3 个交易日内日收盘价格涨幅偏离值累计超过 30%；根据深圳证 券交易所相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 针对公司股票异常波动情况，公司董事会通过电话及现场询问等 方式，对公司控股股东、实际控制人及持股 5%以上股东、公司全体 董事、监事及高级管理人员就相关问题进行了核实，现就相关情况说 明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了与公司相关且市场关注度较 高的未公开重大信息。 3、公司目前的经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东及实际控制人、持有 5%以上股份的股东不存 在关于公司应披 ...

Financial Performance - The company's revenue for Q3 2024 was ¥92,126,731.98, representing a decrease of 32.60% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥6,165,534.97, down 80.41% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was -¥1,511,042.32, a decline of 104.89% compared to the previous year[2]. - Total operating revenue for Q3 2024 was CNY 333,993,687.09, a decrease of 38.5% compared to CNY 542,445,746.24 in the same period last year[13]. - Net profit for Q3 2024 was CNY 74,661,546.28, a decline of 48.3% compared to CNY 144,514,979.02 in Q3 2023[14]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 74,661,546.28, compared to CNY 144,514,979.02 in the same period last year, reflecting a decrease of approximately 48.3%[15]. - Basic and diluted earnings per share for Q3 2024 are both CNY 0.26, down from CNY 0.50 in the previous year, indicating a decline of 48%[15]. Assets and Liabilities - Total assets as of September 30, 2024, were ¥2,437,069,095.83, a decrease of 4.30% from the end of the previous year[2]. - The total assets as of Q3 2024 amounted to CNY 2,437,069,095.83, a decrease from CNY 2,546,570,975.79 at the end of the previous quarter[12]. - Current liabilities totaled CNY 128,361,400.85, down 26.7% from CNY 175,141,355.55 in the previous quarter[12]. - Non-current liabilities amounted to CNY 13,278,812.72, a decrease from CNY 14,744,778.82 in the previous quarter[12]. - The company’s total equity attributable to shareholders decreased by 2.60% to ¥2,295,428,882.26 compared to the end of the previous year[2]. - The total equity attributable to shareholders of the parent company was CNY 2,295,428,882.26, down from CNY 2,356,684,841.42 in the previous quarter[12]. Cash Flow - The company's cash flow from operating activities for the first nine months of 2024 was ¥48,958,629.78, down 41.01% year-on-year[8]. - Cash inflows from operating activities for Q3 2024 amount to CNY 358,511,330.00, a decrease of 29.2% from CNY 506,313,229.59 in Q3 2023[16]. - Net cash flow from operating activities is CNY 48,958,629.78, down 41% from CNY 82,988,321.06 in the same quarter last year[17]. - Cash outflows from investment activities total CNY 1,173,472,855.41, significantly higher than CNY 119,570,288.07 in Q3 2023, indicating a substantial increase in investment expenditures[17]. - The net cash flow from investment activities is -CNY 1,085,211,025.10, compared to -CNY 119,192,777.18 in the previous year, showing a worsening of investment cash flow[17]. - Cash and cash equivalents at the end of Q3 2024 stand at CNY 520,745,020.94, a decrease from CNY 1,729,396,597.93 at the end of Q3 2023, reflecting a decline of approximately 69.9%[17]. - The company reported a cash outflow of CNY 138,240,000.00 for financing activities, up from CNY 96,000,000.00 in the previous year, indicating increased financing costs[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,979, with the top 10 shareholders holding 38.25% of the shares[9]. - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds 110,160,000 shares, accounting for 38.25% of the total[9]. - The top 10 shareholders include both natural persons and corporate entities, with significant stakes held by individuals related to the controlling shareholder[9]. - The company has not reported any changes in the number of preferred shareholders or any significant changes in restricted shares[9]. - The company has not engaged in any major financing or share lending activities during the reporting period[10]. Operational Metrics - The company experienced a 38.43% decline in total revenue for the first nine months of 2024, totaling ¥333,993,687.09, primarily due to reduced sales of ibuprofen[6]. - The basic earnings per share for Q3 2024 was ¥0.02, reflecting an 82.51% decrease compared to the same period last year[2]. - Research and development expenses for Q3 2024 were CNY 26,268,412.71, down 24.8% from CNY 34,932,093.15 in Q3 2023[13]. - The company reported a financial income of CNY 43,297,639.20, an increase from CNY 36,293,249.80 in the same period last year[14]. Changes in Financial Assets - The company reported a significant increase in trading financial assets, which rose by 747.61% to ¥1,096,806,208.33 due to the purchase of transferable large-denomination certificates of deposit[5]. - Trading financial assets increased significantly to ¥1,096,806,208.33 from ¥129,399,817.02[10]. - Accounts receivable rose to ¥65,278,637.33 from ¥52,444,817.42, indicating a growth of approximately 24.5%[10]. - Inventory decreased to ¥155,087,639.39 from ¥173,804,685.14, reflecting a decline of about 10.8%[10]. - Other receivables increased to ¥8,698,567.85 from ¥4,478,312.08, showing a growth of approximately 94.5%[10]. Audit and Compliance - The company has not undergone an audit for the Q3 2024 report[18].

证券代码：301211 证券简称：亨迪药业 公告编号：2024-051 二、董事会会议审议情况 三、备查文件 湖北亨迪药业股份有限公司 第二届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第九次会议 于 2024 年 10 月 14 日以电话及邮件方式送达至全体董事，本次会议于 2024 年 10 月 25 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人，公司监事、高级管理人员列席会议，本次会议由公司董事长程志刚主持。本 次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》的有关规定，会议合法、有效。 会议审议并通过了如下议案： 1、审议通过《2024 年三季度报告》 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）刊载的《2024 年三季度报告》。 表决结果：赞成 8 票，反对 0 票，弃权 0 票。该项议案获审议通过。 2024 年 10 月 25 日 1、湖北亨迪 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2024-052 湖北亨迪药业股份有限公司 第二届监事会第九次会议决议公告 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）刊载的《2024 年三季度报告》。 表决结果：3 票同意、0 票反对、0 票弃权。该项议案获审议通过。 2、《关于对 2024 年三季度报告的审核意见的议案》 经审核，监事会认为董事会编制和审核的公司《2024 年三季度报告》的程 序符合法律、法规和中国证监会的规定，年度报告真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届监事会第九次会议 于 2024 年 10 月 14 日以电话及邮件方式送达至全体监事，本次会议于 2024 年 10 月 25 日以现场方式召开。本次会议应参会监事 3 人，实际参会监事 3 人。会 议由监事会主席陈吉人先生召集并主持。本次会议的召集、召开和表决程序符合 《中华人民 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2024-049 湖北亨迪药业股份有限公司 关于副总经理辞职的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司董事会于近日收到公司副总经理张孝均先生的 书面辞职报告。张孝均先生因到龄退休，申请辞去公司副总经理职务，辞职后不 再担任公司任何职务。目前其所负责的相关工作已顺利交接，辞职不会影响公司 正常生产经营活动。 根据《中华人民共和国公司法》《公司章程》《深圳证券交易所上市公司自 律监管指引第 2 号—创业板上市公司规范运作》等相关法律、法规和规范性文件 的规定，张孝均先生的辞职报告自送达董事会之日起生效。 张孝均先生作为公司副总经理的原定任期为 2023 年 6 月 21 日起至 2026 年 6 月 21 日。截至本公告披露日，张孝均先生未直接持有公司股份，通过荆门市 宁康企业管理中心(有限合伙)间接持有公司股票 646,440 股，间接持股比例 0.23%，张孝均先生配偶及其关联人未持有公司股票。辞去上述职务后，张孝均 先生将继续严格遵守《上市公司股东、董监高减持股份的 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2024-048 湖北亨迪药业股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 根据《上市公司监管指引第2号――上市公司募集资金管理和使用的监管要求》《深圳证 券交易所上市公司自律监管指引第2号――创业板上市公司规范运作》以及《深圳证券交易所 创业板上市公司自律监管指南第2号――公告格式》的相关规定，湖北亨迪药业股份有限公司 （以下简称"公司"）将2024年半年度募集资金存放和使用情况报告如下： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 根据中国证券监督管理委员会"证监许可[2021]3639 号"文《关于同意湖北亨迪业股份 有限公司首次公开发行股票注册的批复》，本公司通过向社会公开发行人民币普通股（A 股） 6,000 万股，发行价 25.80 元，募集资金总额 1,548,000,000.00 元。扣除发行费用后募集资 金净额为人民币 1,400,732,340.85 元。募集资金已于 2021 年 12 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a year-on-year increase of 15%[2]. - The net profit attributable to shareholders reached RMB 100 million, up 20% compared to the same period last year[2]. - The company's operating revenue for the reporting period was ¥241,866,955.11, a decrease of 40.39% compared to the same period last year[12]. - The net profit attributable to shareholders was ¥68,496,011.31, down 39.40% year-on-year[12]. - The basic earnings per share decreased to ¥0.24, a decline of 38.46% compared to the previous year[12]. - The company reported a revenue of 88,025,245.18 for the first half of 2024, with a net profit of 8,108,618.72, indicating a decrease of 334,172.43 compared to the previous period[62]. - The total profit for the first half of 2024 was CNY 73,148,500.75, down from CNY 130,189,130.60 in the same period of 2023, indicating a decline of 43.7%[110]. User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching 1 million active users by the end of June 2024[2]. - The company plans to launch two new products in Q4 2024, targeting a market expansion of 30% in the new therapeutic areas[2]. - The company has outlined a strategic plan for market expansion into Southeast Asia, aiming for a 15% market share by 2025[2]. - The company is actively promoting the implementation of fundraising projects, including a raw material project with an annual output of 700 tons and an anti-tumor raw material project with an annual output of 12 tons[32]. - Market expansion efforts are focused on entering three new provinces, with an estimated market potential of 500 million yuan[143]. Research and Development - Research and development expenses increased by 10% to RMB 50 million, focusing on innovative drug formulations and delivery systems[2]. - The company is investing 100 million yuan in R&D for new technologies aimed at enhancing product efficacy and market competitiveness[144]. - The company aims to enhance its contract development and manufacturing organization (CDMO) services, catering to various stages from preclinical to commercialization[21]. - Research and development expenses for the first half of 2024 were CNY 19,295,692.65, slightly down from CNY 20,214,826.43 in the first half of 2023[107]. Financial Management and Investments - No cash dividends will be distributed for this fiscal year, as the company aims to reinvest profits into growth initiatives[1]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[2]. - The company has raised a total of ¥154,800 million, with a net amount of ¥140,073.23 million after deducting issuance costs, and has cumulatively invested ¥46,994.43 million of the raised funds[45]. - The cumulative proportion of changed use of raised funds reached 62.74%, with a total of ¥87,875.21 million having been repurposed[45]. - The company has ongoing major non-equity investment projects, although specific details were not provided[44]. Environmental Compliance and Sustainability - The company has a wastewater treatment capacity of 3,000 tons per day, with monitoring values for COD and ammonia nitrogen consistently meeting standards of ≤657 mg/L and ≤114 mg/L respectively[72]. - The company has implemented a comprehensive air pollution control system, achieving a VOC emission concentration of less than 60 mg/m³, well below the standard limit of ≤100 mg/m³[71]. - The company has established a hazardous waste management plan and complies with strict disposal regulations, ensuring no hazardous waste exceeded limits during the reporting period[74]. - The company has received multiple environmental approvals, including a recent one in August 2023 for a high-end pharmaceutical internationalization project[71]. Risk Management - The company faces risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[1]. - The company acknowledges the potential negative impact of trade protectionism on its operations, particularly concerning its suppliers and markets in India[63]. - The company faces risks related to safety production, product quality, foreign exchange fluctuations, international trade environment, and pharmaceutical industry policies, which could adversely affect its operations[63][64]. Corporate Governance - The company held its first temporary shareholders' meeting on January 19, 2024, with a participation rate of 61.13%[66]. - The company elected a new chairman of the supervisory board on May 14, 2024, following the retirement of the previous chairman[67]. - The company has not engaged in entrusted financial management, derivative investments, or entrusted loans during the reporting period[57][58]. - The company has not sold any significant assets during the reporting period[59]. Accounting and Financial Reporting - The financial report for the half-year period has not been audited[99]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements are true and complete[134]. - The company has established significant accounting policies to determine the importance of financial statement items based on their impact on economic decisions[133]. - The company recognizes revenue when control of goods or services is transferred to customers, with specific criteria for domestic and international sales[170].

证券代码：301211 证券简称：亨迪药业 公告编号：2024-044 湖北亨迪药业股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第八次会议 于 2024 年 8 月 16 日以电话及邮件方式送达至全体董事，本次会议于 2024 年 8 月 28 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人， 公司监事、高级管理人员列席会议，本次会议由公司董事长程志刚主持。本次董 事会会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规和 《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1、《2024 年半年度报告全文》及摘要 经审议，董事会认为：公司《2024 年半年度报告》及《2024 年半年度报告 摘要》的编制和审核程序符合法律、行政法规和中国证券监督管理委员会、深圳 证券交易所的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存 在任何虚假记载、误 ...